Clinical Trial Update: Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study evaluating Velcade (bortezomib) added to CHOP-Rituximab in untreated diffuse large B-cell lymphoma and mantle cell lymphoma. The trial has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-04-07